Purpose: To assess macular thinning in individuals with prediabetes or type 2 diabetes without diabetic retinopathy (DM2 w/o DR) compared with individuals with normal glucose metabolism (NGM). Methods: Using spectral domain optical coherence tomography (SD-OCT), we measured macular thickness in six subfields as defined by the Early Treatment Diabetic Retinopathy Study (ETDRS) in 1838 participants from The Maastricht Study, a population-based cohort study (mean age 59 AE 8 years, 49% men, 1087 NGM, 279 prediabetes, 472 DM2 w/o DR). Multivariable linear regression was used to assess the association between macular thickness and glucose metabolism status. Results: After adjustment for age, sex and spherical equivalent, individuals with prediabetes showed a significant decrease in pericentral superior macular thickness [b = À2.14 lm (95% confidence interval (CI): À4.24 to À0.03), p < 0.05] compared with individuals with NGM. In individuals with DM2 w/o DR, the fovea [b = À4.05 lm (95% CI: À6.30 to À1.79), p < 0.001] and the four pericentral quadrants (range: b = À4.64 to À5.29 lm, p < 0.001) were significantly thinner compared with individuals with NGM. There was a significant linear trend of macular thinning with severity of glucose metabolism status in five subfields (p < 0.001). Conclusion: Macular thickness is reduced in prediabetes and a greater reduction occurs in DM2, even before DR is clinically present. About half of the thinning observed in DM2 w/o DR was already found in prediabetes. Generalized thinning of the macula could be related to thinning of the temporal side of the optic nerve head through the connecting papillo-macular bundle.
Introduction
Diabetic retinopathy (DR) is a severe complication of diabetes and often goes unnoticed until visual loss occurs. The historical definition of early DR is based on the presence of microaneurysms, which can be detected by ophthalmoscopic examination.
However, in 1980, Simonsen et al. showed the predictive value of the oscillatory potential in the development of proliferative DR (Frost-Larsen et al. 1980; Simonsen 1980 ) and in 1986, Bresnick et al. proposed DR to primarily be a neurosensory disorder (Bresnick 1986) . Also visual acuity, dark adaptation and colour vision are impaired in individuals with diabetes (Henson & North 1979; Sokol et al. 1985; Bresnick 1986; Hardy et al. 1992; Han et al. 2004a,b; Realini et al. 2004; Klemp et al. 2005; Bearse et al. 2006; Ng et al. 2008; Vujosevic et al. 2008; Harrison et al. 2011 ). These early functional deficits could be related to structural changes in the retina as revealed by optical coherence tomography (OCT) in individuals with diabetes. Recent studies suggest that thinning of the neuronal layers of the retina is an early event in the pathogenesis of DR, as these retinal neurodegenerative changes occur even before microvascular lesions can be detected with funduscopy Carrasco et al. 2007 Carrasco et al. , 2008 Garcia-Ramirez et al. 2009; De Clerck et al. 2015) . Therefore, DR has recently been redefined as 'structural and functional changes in the retina due to diabetes' (Gardner et al. 2011) .
Recently, we observed a linear trend of retinal nerve fibre layer (RNFL) thinning around the optic nerve head with worsening of glucose regulation, predominantly at the temporal side of the optic nerve head (De Clerck et al. 2017) . One can hypothesize that also in the macula, retinal neurodegeneration is already present in prediabetes, a stage of glucose dysregulation that occurs before type 2 diabetes. However, population-based studies of macular thickness and glucose metabolism are not available. Establishing changes in macular thickness in individuals with prediabetes and in individuals with DM2 w/o DR could open new perspectives for understanding the early pathogenesis of DR.
The aim of this study was to evaluate to what extent macular thinning occurs in individuals with DM2 w/o DR and also in individuals with prediabetes, as compared to individuals with NGM in a large population-based cohort study.
Materials and Methods

Study population and design
In this study, we used data from The Maastricht Study, an observational prospective population-based cohort study. The rationale and methodology have been described previously (Schram et al. 2014) . In brief, the study focuses on the aetiology, pathophysiology, complications and comorbidities of DM2 and is characterized by an extensive phenotyping approach. Eligible for participation were all individuals aged between 40 and 75 years and living in the southern part of The Netherlands.
Participants were recruited through mass media campaigns and from the municipal registries and the regional Diabetes Patient Registry via mailings. Recruitment was stratified according to known DM2 status for reasons of efficiency. This report includes cross-sectional data from the first 3451 participants, who completed the baseline survey between November 2010 and September 2013. The examinations of each participant were performed within a time window of 3 months. The study has been approved by the institutional medical ethical committee (NL31329.068.10) and the Minister of Health, Welfare and Sports of The Netherlands, on the basis of the Health Council's opinion (Permit 131088-105234-PG) and is compliant with the tenets of the Declaration of Helsinki.
All participants gave written informed consent.
Glucose metabolism status
To determine glucose metabolism status, all participants, except those who used insulin, underwent a standardized 2-hr 75 g oral glucose tolerance test (OGTT) after an overnight fast. For safety reasons, participants with a fasting glucose level above 11.0 mmol/ l, as determined by a finger prick, did not undergo the OGTT. For these individuals (n = 13), fasting glucose level and information about diabetes medication were used to determine glucose metabolism status. Glucose metabolism status was defined according to the WHO (2006) criteria into NGM, impaired fasting glucose (IFG), impaired glucose tolerance (IGT), prediabetes (i.e. IFG and/or IGT) and DM2 (2006) . For this study, individuals with DM1, individuals with latent autoimmune diabetes of adults, steroid-induced diabetes and individuals who underwent a pancreas transplantation were excluded.
Ophthalmologic measurements
Automated refraction was performed in both eyes using an automated refractor (Tonoref II; Nidek, Gamagori, Japan). Once the pupils were dilated with tropicamide 0.5% and phenylephrine 2.5%, fundus photography of both eyes was performed. All fundus photographs were made with an auto fundus camera (Model AFC-230; Nidek) in 45 degrees of at least three fields: one field centred on the optic disc, one field centred on the macula and one temporal field positioned one disc-diameter from the centre of the macula. Diabetic retinopathy (DR) was graded according to the DR Disease Severity Scale and International Clinical DR Disease Severity Scale (American Academy of Ophthalmology Retina/Vitreous Panel 2014). Next, all participants were examined with the Spectralis OCT (Heidelberg Engineering, Heidelberg, Germany, Heidelberg Eye Explorer software version 5.7.5.0) with the eye tracking function enabled. A macular volume scan (17 ART, 73 sections, 60 lm) was performed in both eyes by experienced examiners masked to the conditions of the participants.
Regional numeric data of the macular thickness were derived from the Macular Thickness Map (Massin et al. 2002) . With use of the Macular Thickness Map, macular thickness was measured at the centre, the fovea and in the four pericentral subfields as defined by ETDRS (Fig. 1) . The cross-sections of the macular volume scans were reviewed and scored for the presence of cysts by two experienced graders in a masked fashion based on a prespecified protocol. Individuals with an incomplete volume scan (<73 sections), poor quality imaging (signal-to-noise ratio <20 dB), unsatisfactory automatic realtime tracking (<15) and retinal disorders (i.e. epiretinal membrane, cysts, DR or previous laser treatment) were excluded.
Reproducibility was assessed by two observers in both eyes of nine individuals (seven men, 56.0 AE 5.5 years; four individuals with DM2) who were examined on two occasions spaced 1 week apart. The intra-observer and interobserver intraclass correlation coefficients were ≥0.99 for all macular thicknesses in both eyes.
Statistical analysis
Statistical analysis was performed in SPSS Statistics 23 for Windows (SPSS, IBM, Armonk, NY, USA). Differences between group characteristics were tested using one-way analysis of variance (ANOVA) for continuous variables and chi-squared tests for categorical variables. Multivariable linear regression was used to analyse the association between glucose metabolism status (prediabetes and DM2 w/o DR; determinant) and macular thickness (outcome). We combined the categories IFG and IGT into prediabetes, because analyses did not show differences between IFG and IGT (data not shown). First, a crude analysis was performed. Next, associations were adjusted for age, sex and spherical equivalent by adding these variables as covariates to the model. Interactions between age, sex, spherical equivalent and glucose metabolism status were tested. The results were expressed as regression coefficients (b), representing the mean difference in macular thickness as compared with individuals with NGM, with their 95% CIs. A p value <0.05 was considered statistically significant. Figure 2 shows the flow diagram of the study. From December 2011 to September 2013, 2363 participants from The Maastricht Study underwent OCT measurement. Forty-one participants with DM1 or other types of diabetes were excluded. Participants with an incomplete volume scan (n = 161) or an unsatisfactory quality of measurement (n = 5) were also excluded. In addition, individuals with retinal disorders (n = 160) were excluded -that is epiretinal membrane (n = 92), cysts (n = 42), DR (n = 40) and/or previous laser treatment (n = 18). We additionally excluded individuals where data on the spherical equivalent were missing (n = 158). Thus, 1838 participants were available for analysis with adjustment for age, sex and spherical equivalent. Participants who were excluded due to missing values were more likely to be older (60 AE 8 versus 59 AE 8 years, p < 0.01), to be male (54% versus 49% men, p < 0.01) and to have a lower spherical equivalent (À0.60 AE 2.92 versus À0.27 AE 2.49 D, p < 0.01).
Results
General characteristics
Of the 1838 participants, 1087 participants had NGM (59.1%), 279 participants had prediabetes (15.2%), and 472 participants had DM2 w/o DR (25.7%). Differences in characteristics among these three groups are shown in Table 1 . Figure 3 shows crude pericentral macular thicknesses according to glucose metabolism status. Thinning of the macula was more pronounced with worsening of glucose metabolism status, with a highly significant p-value for linear trend for all quadrants (p < 0.001).
Macular thickness
Age was significantly associated with macular thinning of all pericentral macular thicknesses (range: b = À0.33 to À0.41 per 1 year of age, p < 0.001). In women, all macular thicknesses were thinner compared with men, especially at the fovea (range: b = À1.03 to À12.22 lm, p ≤ 0.01). Macular thinning in women was not significant in the superior quadrant (b = À1.03, p = 0.18). Per dioptre decrease in spherical equivalent, the pericentral macular thickness was 0.16-0.19 lm thinner. However, the association between spherical equivalent and macular thickness was not significant (p > 0.05). In individuals with DM2 w/ o DR, the four pericentral quadrants were significantly associated with duration of diabetes (range: b = À0.36 to À0.42 lm per 1 year of duration, p < 0.05). Table 2 also shows associations adjusted for age, sex and spherical equivalent between glucose metabolism status and centre thickness, foveal thickness and the four pericentral macular thicknesses. After adjustment for age, sex and spherical equivalent, individuals with prediabetes showed a statistically significant decrease in pericentral superior macular thickness [b = À2.14 lm (95% CI: À4.24 to À0.03), p < 0.05] compared with individuals with NGM. In individuals with DM2 w/o DR, the fovea and the four pericentral quadrants were significantly thinner compared with individuals with NGM (range: b = À4.05 to À5.29 lm, p < 0.001). All macular thicknesses decreased with worsening of glucose metabolism status, with a significant pvalue for linear trend for the fovea and the pericentral macular thicknesses (p < 0.001). There were no statistically significant interactions between the variables age, sex, spherical equivalent and glucose metabolism status (p > 0.10). These interaction terms were, therefore, left out of the models. Figure 4 shows the mean difference (b) in pericentral macular thicknesses in individuals with prediabetes and DM2 w/o DR as compared with NGM after adjustment for age, sex and spherical equivalent. About half of the thinning observed in DM2 w/o DR was already found in prediabetes. Thinning of the macula was more pronounced with worsening of glucose metabolism status, with a significant linear trend for all quadrants (p < 0.001).
Discussion
We show for the first time that prediabetes and further worsening of glucose metabolism status are associated with general thinning of the macula in a population-based setting. About half of the thinning observed in DM2 w/o DR was already found in prediabetes. These findings suggest that early neurodegenerative changes are already present in prediabetes, and that these changes are more evident in individuals with DM2 w/o DR in all subfields.
To our knowledge, this is the first study on the association between glucose metabolism status, as defined by an OGTT, and changes in macular thickness. In contrast to previous studies, we used a highly detailed volume scan consisting of 73 B-scans with an excellent inter-and intraobserver reliability to assess the macular thickness. The mean macular thicknesses of all subfields had a small standard error and were very similar between right and left eyes. In individuals with NGM, the pericentral temporal macula was thinner than the other quadrants, which is also similar to previous studies (Sanchez-Tocino et al. 2002; Sugimoto et al. 2005; Browning et al. 2008; Oshitari et al. 2009 ). Thinning of the different pericentral macular subfields is consistent with two previous studies using OCT in individuals with DM2 w/o DR (Sugimoto et al. 2005; Oshitari et al. 2009 ).
We found a highly significant trend of macular thinning from NGM via prediabetes to DM2 w/o DR in all pericentral subfields of both eyes. Previous studies also assessed the macular thickness in individuals with DM2 w/o DR. However, these studies showed discrepancies in results regarding centre thickness, foveal thickness and pericentral macular thicknesses (De Clerck et al. 2015) . These discrepancies may be explained by heterogeneity among these studies in terms of sample size, population characteristics and scan protocol. In addition, none of these studies made adjustments for basic confounding factors such as age, sex and spherical equivalent. Similar to previous studies, we found that ageing is associated with macular thinning (Massin et al. 2002; Sanchez-Tocino et al. 2002; Chan et al. 2006; von Hanno et al. 2017 ). We detected a thinner macular thickness in women compared with men. This has also been described previously (Massin et al. 2002; Chamberlain et al. 2006; von Hanno et al. 2017 ). Controversial results have been reported for the association between spherical equivalent and macular thickness (Zou et al. 2006; Lam et al. 2007; Ooto et al. 2010 Ooto et al. , 2011 von Hanno et al. 2017 ).
We found a non-significant association between a lower spherical equivalent and macular thinning. Our findings regarding the negative correlation between macular thickness and diabetes duration in individuals with type 2 diabetes correspond with previous research in individuals with type 1 diabetes (Sohn et al. 2016) . Macular thinning seems to reflect early neurodegenerative changes in diabetes. Therefore, our findings support the hypothesis that retinal neurodegenerative changes occur before the presence of microvascular changes as assessed with conventional techniques (Friedenwald 1950; Cogan et al. 1961; Barber 2003) and even before the diagnosis of DM2. Previous studies have shown that chronic hyperglycaemia, oxidative stress and accumulation of advanced glycation end products result in an increase in the concentration of glutamate and the loss of neuroprotective factors. Animal studies Barber et al. 2000 Barber et al. , 2005 Rungger-Brandle et al. 2000; Zeng et al. 2000; Kim et al. 2004; Martin et al. 2004; Gastinger et al. 2006; Tang et al. 2011; Bogdanov et al. 2014; Arroba et al. 2016 ) and human studies (Wolter 1961; Bloodworth 1962; Barber et al. 1998; Mizutani et al. 1998; Abu-El-Asrar et al. 2004) have demonstrated that these insults can result in glial activation, neuronal apoptosis, thinning of the neuronal layers in the retina and an increase in vascular endothelial growth factor. This leads to vasoregression, an impaired hemodynamic response and a breakdown of the blood-retinal barrier, resulting in early microvascular changes, and in a later stage to accumulation of extravascular fluid, which can result in cystoid macular oedema (Cunha-Vaz et al. 1975; Simonett et al. 2017) . Finally, inflammatory factors and a low number or dysfunction of endothelial progenitor cells also play a role in these microvascular and neurodegenerative changes (Simo & Hernandez 2014) . In prediabetes and DM2 w/o DR, we observed macular thinning in all subfields, whereas in the RNFL around the optic nerve head, only the temporal half was affected in our earlier study in the same population (De Clerck et al. 2017 ). This may be explained by damage to the papillo-macular bundle and its neighbouring bundles emanating from ganglion cells all over the macula, together with their axons, forming nerve fibre bundles predominantly connected with the temporal RNFL around the optic nerve head (Lee et al. 2012) . This thinning reflects a decrease in the number of retinal nerve fibres and ganglion cells (van Dijk et al. 2010; Kim et al. 2015) . Ganglion cells are sensitive to oxidative stress and to diabetes-related neurodegenerative changes (Kergoat et al. 2006; Kern & Barber 2008) . Retinal nerve fibre layer (RNFL) thinning around the optic nerve head and macular thinning could occur secondary to neuronal apoptosis by metabolic stress or alterations in the nerve fibre connections between the optic nerve head and the macula. Furthermore, parvocellular axons from the papillo-macular bundle are more sensitive to early metabolic changes (Stricker et al. 2011) .
A previous study showed preferential thinning of the inner retinal layers in individuals with type 2 diabetes (van Dijk et al. 2012) . Recent studies suggest that there is a direct relationship between axonal loss and visual function, as a decrease in ganglion cells and their axons, as measured by SD-OCT, is related to visual field loss in individuals with glaucoma (Bogunovic et al. 2015) . Therefore, macular ganglion cell parameters are not only affected in individuals with diabetes, but also seem to be more appropriate for the diagnosis of glaucoma than measuring the RNFL thickness around the optic nerve head (Kim et al. 2011; Moreno et al. 2011; Rimayanti et al. 2014; Ng et al. 2015) .
Neurodegenerative macular thinning in prediabetes suggests that DR begins in the earliest stages of glucose dysregulation, early in the progression from NGM to frank diabetes, which lasts 7 years on average (Ramlo-Halsted & Edelman 1999) . This is an important finding as glucose dysregulation is amenable to treatment and may thus be a target to prevent neurodegenerative changes in the retina in DM2. Early identification, lifestyle modification and treatment of cardiovascular risk factors in individuals with prediabetes have the potential to reduce both the incidence of diabetes and the DR (McKinlay & Marceau 2000; Olafsdottir et al. 2016; Larsen et al. 2017) . Therefore, the first step may be to identify prediabetes rather than focusing on detecting microvascular changes using ophthalmoscopy to reduce the burden of diabetes on ocular changes, whether neuronal and (or) vascular.
Due to the later implementation of the OCT measurements, it is possible that our sample is not truly populationbased. The missing participants, however, were older, suggesting that, if anything, macular thinning in the total study population of the Maastricht Study is expected to be greater than reported here. This study has a crosssectional design and does not allow conclusions on cause-and-effect relations. However, by comparing individuals with NGM, prediabetes and DM2 w/o DR, we simulate the pathological pathway of glucose metabolism deterioration.
Future studies should focus on causality and underlying mechanisms of macular thinning in prediabetes and DM2 and should also quantify the thickness of the separate layers of the retina, because these layers can be affected differently by diabetes (van Dijk et al. 2012) . In addition, the link between these structural changes and functional changes, such as visual field loss, needs to be studied further. Moreover, future studies should assess whether neurodegenerative changes in the macula are related to the presence of neuropathy and nephropathy in individuals with prediabetes and DM2.
In conclusion, macular thickness is reduced in prediabetes and a greater reduction occurs in DM2, even before DR is clinically present. About half of the thinning observed in DM2 w/o DR was already found in prediabetes. Generalized thinning of the macula could be related to thinning of the temporal side of the optic nerve head through the connecting papillo-macular bundle.
